BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11114733)

  • 1. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
    Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
    Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
    Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
    Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
    van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
    Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of somatic FGFR3 mutation in various types of carcinoma.
    Karoui M; Hofmann-Radvanyi H; Zimmermann U; Couvelard A; Degott C; Faridoni-Laurens L; Ahomadegbe JC; Gazzeri S; Brambilla E; Clerici T; Charbonnier P; Tresallet C; Mitry E; Penna C; Rougier P; Boileau C; Thiery JP; Nordlinger B; Franc B; Radvanyi F
    Oncogene; 2001 Aug; 20(36):5059-61. PubMed ID: 11526491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
    Cappellen D; De Oliveira C; Ricol D; de Medina S; Bourdin J; Sastre-Garau X; Chopin D; Thiery JP; Radvanyi F
    Nat Genet; 1999 Sep; 23(1):18-20. PubMed ID: 10471491
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
    Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
    Sibley K; Cuthbert-Heavens D; Knowles MA
    Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.
    Jang JH; Shin KH; Park JG
    Cancer Res; 2001 May; 61(9):3541-3. PubMed ID: 11325814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
    Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
    Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
    Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
    Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
    Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
    Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
    Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
    Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.
    Sibley K; Stern P; Knowles MA
    Oncogene; 2001 Jul; 20(32):4416-8. PubMed ID: 11466624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
    Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
    Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.
    van Rhijn BW; Lurkin I; Chopin DK; Kirkels WJ; Thiery JP; van der Kwast TH; Radvanyi F; Zwarthoff EC
    Clin Cancer Res; 2003 Jan; 9(1):257-63. PubMed ID: 12538478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
    Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
    Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
    Meyers GA; Orlow SJ; Munro IR; Przylepa KA; Jabs EW
    Nat Genet; 1995 Dec; 11(4):462-4. PubMed ID: 7493034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.